Viridian Therapeutics, Inc. (LON:0K1R)

Market Cap	2.10B +71.9%
Revenue (ttm)	52.66M +23,340.1%
Net Income	-182.50M
EPS	-2.25
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21
Average Volume	555
Open	30.22
Previous Close	30.25
Day's Range	28.63 - 30.36
52-Week Range	9.99 - 34.31
Beta	0.98
RSI	37.33
Earnings Date	Feb 27, 2026

About Viridian Therapeutics

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of e...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 143
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K1R

Financial Performance

In 2024, Viridian Therapeutics's revenue was $302,000, a decrease of -3.82% compared to the previous year's $314,000. Losses were -$208.56 million, 19.2% more than in 2023.

Financial numbers in USD